EG 427, a Paris, France-based biotechnology company developing pinpoint DNA medicine solutions, raised additional €5M in funding.
The round, which brought the total amount to €18M, saw participation from a combination of existing investors and new family office investors.
The company intends to use the funds to finance clinical development of EG110A and advance other pipeline products.
Led by Philippe Chambon, M.D., Ph.D., Founder and CEO, and Cornelia Haag-Molkenteller, MD, PhD, Chief Medical Officer, EG 427 has developed a non-replicative Herpes Simplex Virus type 1 (nrHSV-1) based vector platform which delivers, with pinpoint precision, highly selective, durable expression of disease modifying transgenes. The company leverages the technology to design new treatments of peripheral nervous system disorders and beyond. Its lead asset, EG110A, targets the silencing of type-C sensory neurons.
Later this year, EG 427 will be initiating a Series B fundraising to finance clinical development of EG110A and advance other pipeline products.
FinSMEs
13/07/2023